Genomic Health Announces Oncotype DX® Breast Cancer Assay Meets Blue Cross and Blue Shield Association Technology Evaluation Center Criteria

REDWOOD CITY, Calif., July 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that during the Blue Cross and Blue Shield Association Medical Advisory Panel meeting on June 28, 2007, the panel concluded that use of Genomic Health's Oncotype DX breast cancer assay to inform decision making about adjuvant chemotherapy meets the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC) criteria for women with estrogen receptor-positive, node-negative, tamoxifen-treated breast cancer. The decision is posted at http://www.bcbs.com/betterknowledge/tec/press/actions-taken-by-the-medical-1.html.

"The conclusion that the use of Oncotype DX to inform decision making about adjuvant chemotherapy meets TEC criteria is a substantial step forward for the field of personalized medicine," said Randy Scott, Ph.D., chairman and chief executive officer of Genomic Health. "This assessment affirms our belief that clinical evidence is the foundation for improving treatment decisions and strongly supports the clinical utility of Oncotype DX."

The Technology Evaluation Center

Founded in 1985 by the Blue Cross and Blue Shield Association, the Technology Evaluation Center pioneered the development of scientific criteria for assessing medical technologies through comprehensive reviews of clinical evidence. TEC operates as part of the Association's Office of Clinical Affairs and its assessments are scientific opinions, provided solely for informational purposes.

About Oncotype DX

Oncotype DX represents the first diagnostic multi-gene expression test service commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 2,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, over 5,500 physicians have ordered a cumulative total of more than 27,000 tests and approximately 125 million lives are now covered by reimbursement contracts and agreements. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com. Genomic Health, the Genomic Health logo and Oncotype DX are our trademarks or registered trademarks.

SOURCE Genomic Health, Inc.

Investors, Brad Cole, +1-650-569-2281, investors@genomichealth.com, or media, Emily Faucette, +1-650-569-2824, media@genomichealth.com, both of Genomic Health

http://www.genomichealth.com

Copyright © 2007 PR Newswire. All rights reserved

News Provided by COMTEX

Faucette, +1-650-569-2824, media@genomichealth.com, both of Genomic Health

http://www.genomichealth.com

Copyright © 2007 PR Newswire. All rights reserved

News Provided by COMTEX

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

  

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

 

Shareholder Tools

  

DISCLAIMER

The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.


Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.